---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041949"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:28:30.685883+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences delays KZR-261 dose expansion to 2024, still enrolling Cohort 7

## Summary
- Phase 1 trial of KZR-261 in solid tumors enrolling Cohort 7 (40 mg/m2); no MTD reached yet.
- Revised forecast pushes safety/dose escalation data report and dose expansion start to 2024.
- Topline data from expansion portion to be reported when available.
- Trial evaluates safety, PK/PD, and preliminary anti-tumor activity in locally advanced/metastatic disease.

## SEC filing metadata
- accession: 0000950170-23-041949
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023041949/0000950170-23-041949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023041949/kzr-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041949
- JSON: https://secwatch.observer/filing/0000950170-23-041949.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.